Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D

類似資料

• Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines
  著者:: Davidoff, Amy J., 等
  出版事項: (2013)
• Effect of Erythropoiesis-Stimulating Agent Policy Decisions on Off-Label Use in Myelodysplastic Syndromes
  著者:: Hendrick, Franklin, 等
  出版事項: (2014)
• How Low‐Income Subsidy Recipients Respond to Medicare Part D Cost Sharing
  著者:: Stuart, Bruce, 等
  出版事項: (2016)
• Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response
  著者:: Duong, Vu H., 等
  出版事項: (2015)
• Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes
  著者:: Zeidan, Amer M, 等
  出版事項: (2015)